8-K: Vicarious Surgical Executives Take Salary Cuts Amid Delisting

Vicarious Surgical Inc. announced executive salary reductions for its President and CTO, coinciding with its delisting from the NYSE.

Summary

• Vicarious Surgical Inc. entered into amendments to the Executive Employment Agreements for Adam Sachs, President, and Sammy Khalifa, Chief Technology Officer, effective March 9, 2026.
• Adam Sachs' annual base salary was reduced by approximately 50% from $541,619.04 to $270,810.02.
• Sammy Khalifa's annual base salary was reduced by approximately 25% from $424,800.00 to $318,600.10.
• Despite the salary reductions, target bonus amounts and severance payments will continue to be calculated based on the executives' higher base salaries prior to these amendments.
• Both executives voluntarily agreed to the salary reductions, and these reductions will not constitute 'Good Reason' for severance benefits under their agreements.
• The New York Stock Exchange commenced proceedings on March 3, 2026, to delist and immediately suspend trading in Vicarious Surgical Inc.'s Class A common stock.
• The company's Class A common stock is now quoted on the OTCID market tier under the symbol RBOT.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, primarily due to the significant executive salary cuts and the severe blow of delisting from the NYSE, indicating substantial operational or financial challenges.

Negatives

• Adam Sachs, President, experienced a significant 50% reduction in his annual base salary, from approximately $541,619 to $270,810.
• Sammy Khalifa, Chief Technology Officer, experienced a 25% reduction in his annual base salary, from approximately $424,800 to $318,600.
• The company's Class A common stock was delisted from the New York Stock Exchange on March 3, 2026, and trading was immediately suspended.
• The stock is now quoted on the OTCID market, which typically implies reduced liquidity and investor interest compared to a major exchange.

Risks

• The delisting from the New York Stock Exchange to the OTCID market may lead to decreased liquidity and investor confidence.
• Reduced executive salaries, even if voluntary, could signal financial distress or a need for significant cost-cutting within the company.
• Operating on the OTC market may limit the company's access to capital and its ability to attract institutional investors.
• The company's ability to retain key talent might be impacted by significant salary reductions, despite the waiver of 'Good Reason' for severance.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the effective date of the salary amendments. The delisting from NYSE suggests a challenging outlook for the company's public market presence.

Management Comments

• Adam Sachs and Sammy Khalifa voluntarily agreed to amend their employment agreements and reduce their base salaries.
• The executives expressly waived any right to assert that the salary reduction constitutes 'Good Reason' for severance benefits.

Industry Context

StockSavvy.ai notes that executive salary reductions, especially of this magnitude, often occur in companies facing significant financial headwinds or strategic restructuring. For a surgical robotics company, this could indicate challenges in product development, market adoption, or securing necessary funding. The delisting from a major exchange like the NYSE to the OTC market is a severe blow to a company's standing, typically signaling a loss of investor confidence and potentially hindering future capital-raising efforts. This move places Vicarious Surgical in a less visible and less liquid trading environment compared to its peers in the medical technology and robotics sector.

Comparison to Industry Standards

• Executive salary reductions of 25-50% are highly unusual for a publicly traded company, especially for key leadership roles like President and CTO, unless the company is in severe financial distress or undergoing a major restructuring. In a healthy, growing surgical robotics company, executive compensation typically aligns with industry benchmarks for attracting and retaining top talent.
• Delisting from the New York Stock Exchange is a significant negative event, contrasting sharply with industry leaders in medical robotics such as Intuitive Surgical (ISRG) or Stryker (SYK), which maintain strong presences on major exchanges. Such delisting often results from failing to meet listing requirements (e.g., minimum share price, market capitalization, or financial reporting standards) and severely impacts a company's credibility and access to institutional capital, which is critical for capital-intensive R&D in the medical device sector.

Stakeholder Impact

• Shareholders: Likely to experience decreased share price, reduced liquidity, and diminished investor confidence due to the delisting and executive salary cuts. The move to the OTC market typically makes shares less attractive and harder to trade.
• Employees: While not directly stated, significant executive salary reductions could signal broader financial difficulties, potentially impacting employee morale, future compensation, or job security.
• Creditors: May view the company as a higher credit risk due to the financial challenges implied by the salary cuts and delisting.

Key Dates

Recommendation

The combination of significant executive salary reductions and the delisting from the New York Stock Exchange to the OTC market are strong indicators of severe financial distress and a deteriorating business outlook. These events typically lead to a substantial loss of investor confidence, reduced liquidity, and a higher risk profile, making the stock a strong sell for seasoned investors and institutions.

Keywords

Vicarious Surgical, RBOT, Executive Compensation, Salary Reduction, NYSE Delisting, OTC Market, 8-K Filing, Corporate Governance, Surgical Robotics